BioMed Stock Movers: DNDN, EXAS, KG Print
Wednesday, 08 April 2009 10:26

Dendreon (DNDN) has stalled out around $6.50 per share after a major rally on news of upcoming presentation at a medical conference later this month. DNDN expects to report Provenge clinical trial results some time before the end of April, although it did not guarantee this would occur at the upcoming presentation.

The recent spike in shares of DNDN and upcoming presentation do not provide any clarity on whether Provenge results will be sufficient for attaining FDA approval and the pending data release will determine the

Company's fate.

http://biomedreports.com/articles/most-popular/767-fda-calendar-updates-snts-ceph-azn-dndn-gild-nvo.html 

King Pharma (KG) on Goldman's conviction buy list with $10 price target

Check out my article at

http://biomedreports.com/articles/most-popular/683-king-pharma-a-value-play-on-new-drug-approvals.html

EXACT Sciences (EXAS) moving up steadily since briefly moving below a dollar late last week. EXAS trading on light volumes this week, but moving to the

Error. Page cannot be displayed. Please contact your service provider for more details. (18)

upside with last trade at $1.19 today. Below is a link to my two latest articles on EXAS:

http://biomedreports.com/articles/latest-news/678-exact-sciences-announces-new-management-team.html

Disclosure: I own shares of EXAS.



BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the
'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
  BMR:1